These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36998459)

  • 1. Cost-effectiveness evaluation based on two models of first-line atezolizumab monotherapy and chemotherapy for advanced non-small cell lung cancer with high-PDL1 expression.
    Zhang C; Liu Y; Tan J; Tian P; Li W
    Front Oncol; 2023; 13():1093469. PubMed ID: 36998459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
    Liu G; Kang S; Wang X; Shang F
    Front Oncol; 2021; 11():669195. PubMed ID: 33987103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy.
    Chen P; Yang Q; Li Y; Jing X; Chen J
    Front Oncol; 2022; 12():894656. PubMed ID: 36158650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab compared to chemotherapy for first-line treatment in non-small cell lung cancer with high PD-L1 expression: a cost-effectiveness analysis from US and Chinese perspectives.
    Cheng S; Pei R; Li J; Li B; Tang L; Yin T; Liu S
    Ann Transl Med; 2021 Sep; 9(18):1481. PubMed ID: 34734033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
    Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
    Adv Ther; 2021 May; 38(5):2447-2457. PubMed ID: 33821431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
    Chisaki Y; Nakano H; Minamide J; Yano Y
    Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
    Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
    [No Abstract]   [Full Text] [Related]  

  • 8. Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.
    Xiang G; Gu L; Chen X; Wang F; Chen B; Zhao J; Lu Y; Chang F; Zhu Y
    Front Public Health; 2021; 9():743558. PubMed ID: 34957008
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study.
    Plessala I; Cawston H; Cortes J; Ajjouri R; Le Lay K; Souquet PJ; Chouaid C
    Lung Cancer; 2023 Oct; 184():107316. PubMed ID: 37562344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China.
    Shang F; Zhang B; Kang S
    Expert Rev Pharmacoecon Outcomes Res; 2023 Mar; 23(3):337-343. PubMed ID: 36655382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer.
    Phua LC; Lee SC; Ng K; Abdul Aziz MI
    BMC Health Serv Res; 2020 Jun; 20(1):581. PubMed ID: 32580722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.
    Isla D; Lopez-Brea M; Espinosa M; Arrabal N; Pérez-Parente D; Carcedo D; Bernabé-Caro R
    Cost Eff Resour Alloc; 2023 Jan; 21(1):6. PubMed ID: 36647072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.
    Jiang Y; Zhao M; Xi J; Li J; Tang W; Zheng X
    Front Public Health; 2023; 11():1282374. PubMed ID: 37841712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
    Huo G; Liu W; Kang S; Chen P
    Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
    Qin S; Yi L; Li S; Tan C; Zeng X; Wang L; Peng Y; Wan X
    Adv Ther; 2021 Jun; 38(6):3399-3408. PubMed ID: 34019245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens.
    Li LF; Qi R; Wei TT; Feng L; Zhang X; Liu Q
    Risk Manag Healthc Policy; 2024; 17():927-933. PubMed ID: 38628395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
    Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
    Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.